Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

564 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.
Hurtado-Guerrero I, Hernáez B, Pinto-Medel MJ, Calonge E, Rodriguez-Bada JL, Urbaneja P, Alonso A, Mena-Vázquez N, Aliaga P, Issazadeh-Navikas S, Pavia J, Leyva L, Alcamí J, Alcamí A, Fernández Ó, Oliver-Martos B. Hurtado-Guerrero I, et al. Among authors: fernandez o. J Clin Med. 2020 Mar 31;9(4):959. doi: 10.3390/jcm9040959. J Clin Med. 2020. PMID: 32244308 Free PMC article.
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B. Órpez-Zafra T, et al. Among authors: fernandez o. Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9. Mult Scler. 2017. PMID: 27613121
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Meca-Lallana JE, Oreja-Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió-Torrentà L, Meca-Lallana V, Hernández MA, Marzo ME, Álvarez-Cermeño JC, Rodríguez-Antigüedad A, Montalbán X, Fernández O; Spanish GILENYA Registry Investigators. Meca-Lallana JE, et al. Among authors: fernandez o. PLoS One. 2021 Oct 13;16(10):e0258437. doi: 10.1371/journal.pone.0258437. eCollection 2021. PLoS One. 2021. PMID: 34644366 Free PMC article.
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva L, Fernández O, Fedetz M, Blanco E, Fernández VE, Oliver B, León A, Pinto-Medel MJ, Mayorga C, Guerrero M, Luque G, Alcina A, Matesanz F. Leyva L, et al. Among authors: fernandez o, fernandez ve. J Neuroimmunol. 2005 Jun;163(1-2):165-71. doi: 10.1016/j.jneuroim.2005.02.010. Epub 2005 Apr 22. J Neuroimmunol. 2005. PMID: 15885318
Interferon receptor expression in multiple sclerosis patients.
Oliver B, Mayorga C, Fernández V, Leyva L, León A, Luque G, López JC, Tamayo JA, Pinto-Medel MJ, de Ramon E, Blanco E, Alonso A, Fernández O. Oliver B, et al. Among authors: fernandez v, fernandez o. J Neuroimmunol. 2007 Feb;183(1-2):225-31. doi: 10.1016/j.jneuroim.2006.11.010. Epub 2006 Dec 26. J Neuroimmunol. 2007. PMID: 17188754
564 results